Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74.2% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen BioNTech BNTX

BioNTech live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Forex candlestick chart of JPY/USD currency pair trends.
Vanessa L 2025 Jan 17, 10:00

Forex Prop Trading Updates and Income Levels' Impact on Forex

Forex JPY USD
Bitcoin price action is shown on a trading chart, with a British flag in the background.
Vanessa L 2025 Jan 17, 09:00

Bitcoin Price Action Muted: A Complete Guide on How to Buy Bitcoins in the UK

Cryptocurrencies
Frances Wang 2025 Jan 16, 16:00

S&P 500 and Nasdaq 100 Update: Strong Earnings Drive Market Gains

Indices
Frances Wang 2025 Jan 16, 16:00

Oil price today: Oil Prices Climb Amid Supply Fears

Oil
Frances Wang 2025 Jan 16, 16:00

Forex market update: GBP/USD, USD/JPY Forecast

Forex
Darius Anucauskas 2025 Jan 16, 16:00

Week Ahead: Japanese CPI and the BoJ rate hike on the watch, All eyes on the Canada inflation and Trump inauguration

The person silhouette with fluctuating red and green stock charts, symbolizes uncertainty.
Vanessa L 2025 Jan 16, 11:00

Why Is the Stock Market Going Down Today and Are Interest Rates Going Down?

Stocks Shares
A tanker carrying heating oil on a foggy morning, symbolizes the global energy trade.
Vanessa L 2025 Jan 16, 09:02

What Influences the Price of Heating Oil Per Gallon Today? Insights on Futures Contract Crude Oil

Oil Commodities

Info

Spread

1.1513

Spread (%)

1.0343 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Dinsdag

14:31 - 20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

Vrijdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

27033083904

Uitstaande aandelen

239740000

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

2022-06-17

Ex-dividenddatum

2022-06-02

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-2

Meer informatie over dit instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat